Evicenter
P&T meetings

Molgramostim Inhalation Solution

Autoimmune pulmonary alveolar proteinosis

Manufacturer
Savara
Regulatory submission
BLA resubmitted December 2025
Launch
Not announced
89 sources

Section 5 of 6

Economic information and modeling report

3 evidence topics · 1 source

Modeling overview

Summary

No product-specific comparative budget impact model was identified. The Dutch horizon scan estimates annual treatment cost at €100,000–500,000 per patient, expected annual patient volume below 100, and potential total annual expenditure of €30 million. These are prospective horizon-scan estimates. The page does not present comparator costs, treatment uptake over time, healthcare cost offsets, or scenario analyses that would establish incremental budget impact. The estimates do not establish a U.S. acquisition price or a U.S. payer-specific budget impact.

Prospective Dutch patient volume and total annual expenditure

Horizon-scan measureReported estimate
Expected patient volume per year“< 100”
Potential total cost per year“€ 30,000,000.00”

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.